Scarica l'app Stockscreener
27.15
1.76%
0.47
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$26.68
Aprire:
$26.75
Volume 24 ore:
1.27M
Relative Volume:
0.67
Capitalizzazione di mercato:
$4.59B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
150.83
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
-1.06%
1M Prestazione:
+12.52%
6M Prestazione:
+24.89%
1 anno Prestazione:
+57.30%
Intervallo 1D:
$26.42
$27.28
Intervallo di 1 settimana:
$26.38
$27.73
Portata 52W:
$13.40
$27.73
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Confronta ACAD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
27.15 | 4.51B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-05-21 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
TFG Asset Management GP Ltd Has $3.48 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Eventide Asset Management LLC Trims Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Birchview Capital LP Sells 75,600 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
FDA approves powder formulation of trofinetide for Rett syndrome - Contemporary Pediatrics
FDA Approves New Formulation for Acadia Pharmaceuticals' (ACAD) Rett Syndrome Treatment - GuruFocus
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - The Joplin Globe
STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Business Wire
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $928,000 Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals stock price target raised by Stifel to $25 from $24 - Investing.com Canada
Should ACADIA’s Earnings Beat and Conference Highlights Require Action From ACADIA Pharmaceuticals (ACAD) Investors? - Sahm
Stifel Nicolaus Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat
Stifel Maintains Hold Rating and Raises Price Target for ACAD to $25.00 | ACAD Stock News - GuruFocus
What drives ACADIA Pharmaceuticals Inc stock priceReal Estate Investment Trusts & Affordable Market Investment - earlytimes.in
Norges Bank Invests $31.68 Million in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. $ACAD Shares Bought by First Trust Advisors LP - MarketBeat
(ACAD) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Marshall Wace LLP Purchases 1,639,315 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Swing Trade: Can ACADIA Pharmaceuticals Inc stock maintain growth trajectoryJuly 2025 Short Interest & Verified Stock Trade Ideas - moha.gov.vn
Assessing ACADIA Pharmaceuticals Valuation After Strong 2024 Share Price Rally - Yahoo Finance
MACD Signal: Is ACADIA Pharmaceuticals Inc stock a buy in volatile marketsJuly 2025 Market Mood & Community Consensus Trade Signals - moha.gov.vn
ACADIA Pharmaceuticals (ACAD) Is Up 9.6% After Earnings Beat And NUPLAZID Patent Extension News - Yahoo Finance
Assessing Acadia Pharmaceuticals (ACAD) Valuation After Strong Q3 Results and Extended NUPLAZID Patent Protection - Yahoo Finance
State Board of Administration of Florida Retirement System Increases Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (ACAD) Receives a Buy from UBS - The Globe and Mail
ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 12-Month HighShould You Buy? - MarketBeat
Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report? - sharewise.com
Is ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Recent Stock Performance Tethered To Its Strong Fundamentals? - 富途牛牛
Stonepine Capital Management LLC Has $4.85 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals stock hits 52-week high at 26.65 USD By Investing.com - Investing.com Nigeria
Fisher Asset Management LLC Sells 44,710 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Edgestream Partners L.P. Sells 47,964 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Is ACADIA Pharmaceuticals Inc. stock safe for conservative investorsQuarterly Performance Summary & Weekly High Return Stock Opportunities - Newser
Acadia Pharmaceuticals (ACAD): Reassessing Valuation After Strong Q3 Earnings Beat and Higher Analyst Price Targets - Sahm
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality (ACAD) - Seeking Alpha
Acadia Pharmaceuticals stock hits 52-week high at 26.65 USD - Investing.com India
UBS Adjusts ACADIA Pharmaceuticals Price Target to $35 From $39, Maintains Buy Rating - marketscreener.com
Acadia Pharmaceuticals stock price target lowered to $35 at UBS By Investing.com - Investing.com UK
Can ACADIA Pharmaceuticals Inc. stock maintain operating margins2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - Newser
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - The Motley Fool
Acadia to pivot to Alzheimer’s psychosis pipeline, accd to Wall Street analysts - Yahoo Finance UK
Capital Fund Management S.A. Reduces Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
How ACADIA Pharmaceuticals Inc. stock benefits from tech adoption2025 Trading Volume Trends & AI Driven Stock Price Forecasts - Newser
ACADIA Pharmaceuticals (ACAD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Mizuho Maintains 'Neutral' Rating on ACAD, Raises Price Target t - GuruFocus
Acadia Pharmaceuticals stock price target raised by Mizuho to $29 - Investing.com Canada
ACADIA Pharmaceuticals Inc Stock Analysis and ForecastCurrency Fluctuation Impact & Free Trading Psychology Sessions - earlytimes.in
F m Investments LLC Lowers Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Ensign Peak Advisors Inc Cuts Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
American Century Companies Inc. Sells 65,361 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Is ACADIA Pharmaceuticals Inc a good long term investmentEvening Star Patterns & High Profit Growth Stocks - earlytimes.in
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):